A Study to Assess the Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients with a History of Cancer: The SAPPHIRE Registry

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Tofacitinib (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary) ; Anti-TNF monoclonal antibodies; Immunomodulators
Indications Inflammatory bowel diseases
Focus Adverse reactions

23 May 2021 Results (n=231) presented at the Digestive Disease Week 2021
23 May 2021 Status changed to recruiting, according to Results presented at the Digestive Disease Week 2021
10 Jul 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com